An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol.
Emmanuel Peprah, Joyce Gyamfi, John Patena...
https://pubmed.ncbi.nlm.nih.gov/39774400/Actively Recruiting
Led by New York University · Updated on 2026-07-07
900
Participants Needed
1
Research Sites
48 weeks
Total Duration
This research aims to improve the use of hydroxyurea HU for managing sickle cell disease SCD in Nigeria, where most patients currently do not receive evidence-based care despite HUs potential to reduce complications and mortality. The study addresses provider barriers to HU adoption using a practical approach based on previous NIH-funded trials and Nigerian health guidelines. It focuses on increasing HU adoption by healthcare providers through a tailored strategy in clinical settings. The study compares two approaches at 20 clinical sites one group receives educational information about task sharing SIM, and the other group receives an enhanced strategy called TASSH TCP, which includes healthcare worker training, clinical reminders, and practice facilitation to support SCD management. The study follows a cluster randomized design to assess which approach leads to better adoption of HU treatment over 12 months. The implementation and sustainability of these methods are also evaluated at 12 and 24 months. Participants include SCD patients registered at local clinical sites, with assessments including screening, HU treatment initiation, and dosage monitoring at 12 months. Data on adoption rates, implementation fidelity, and mediators affecting these outcomes are collected. The study will help identify scalable and sustainable ways to improve HU use in Nigeria and monitor patient outcomes through electronic medical records over the study period, which runs until May 2028.
CONDITIONS
mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria
E
Emmanuel Peprah, PhD
O
Obiageli Nnodu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
New York University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive either educational information only or an enhanced training and support program to help healthcare providers adopt hydroxyurea treatment for sickle cell disease.
Regular visits depending on clinical site activity
Duration - Up to 24 months
Researchers evaluate the adoption, fidelity, and sustainability of hydroxyurea treatment strategies at 12 and 24 months after implementation.
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Emmanuel Peprah, Joyce Gyamfi, John Patena...
https://pubmed.ncbi.nlm.nih.gov/39774400/New York University
Lead Sponsor